StemCells plans PII for human CNS stem cells in rare myelination disorder
This article was originally published in Scrip
Executive Summary
StemCells Inc said it is 'actively moving forward' with plans to conduct a controlled Phase II trial of its purified human neural stem cells (HuCNS-SC) in patients with Pelizaeus-Merzbacher disease (PMD) whilst also evaluating its next steps with respect to investigating the product in other myelination disorders.